Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf117 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Mar Masiá und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, HIV-1, Virus Shedding. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Background
The impact of long-acting injectable cabotegravir plus rilpivirine (CAB/RPV) on rectal human immunodeficiency virus 1 (HIV-1) RNA dynamics and the factors associated with viral shedding remain poorly understood.
Methods
This prospective study evaluated HIV-1 RNA dynamics by analyzing sequential paired plasma and rectal fluid samples from virologically suppressed individuals who transitioned from oral antiretroviral therapy (ART) to every-2-month CAB/RPV (preceded or not by oral lead-in), over a 9-month follow-up period. RPV trough concentrations were measured in 384 rectal samples.
Results
In total, 597 plasma and 561 rectal samples from 90 participants were analyzed. HIV-1 RNA >50 (>1.69 log10) copies/swab was detected in 14.7% (59/401) of rectal samples (42.2% of participants) during intramuscular CAB/RPV, and in 17.5% (28/160) of rectal samples (29% of participants) during oral ART. Median detectable rectal HIV-1 RNA level during intramuscular ART was 362 (range, 133–2216) copies/swab. The frequency and quantity of rectal shedding did not differ between groups with/without oral lead-in. No correlation was observed between rectal shedding and detectable plasma HIV-1 RNA. Median rectal RPV concentration was 3.07 (quartile 1–quartile 3, 2.83–3.35) log10 ng/swab, 1.6-fold above the 90% maximum effective concentration (EC90) for rectal tissue, and did not correlate with rectal HIV-1 RNA levels. Rectal shedding was associated with plasma pre-ART HIV-1 RNA >5 log10 in multivariate Cox regression, but was unrelated to established predictors of virological failure with CAB/RPV.
Conclusions
Rectal HIV-1 shedding is common during bimonthly intramuscular CAB/RPV treatment and is also observed with oral ART. Shedding was independent of concurrent plasma HIV-1 RNA and rectal RPV concentrations, and was associated with pre-ART viral load.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain.
- Department of Clinical Medicine, Universidad Miguel Hernández, San Juan de Alicante, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
- Institute for Research, Development, and Innovation in Health Biotechnology of Elche, Universidad Miguel Hernández, Elche, Spain.
- Microbiology Service, Hospital General Universitario de Elche, Elche, Spain.
ORCID-Profile: Mar Masiá, Marta Fernández-González, Christian Ledesma, Maria Losada-Echeberría, Nieves Gonzalo-Jiménez, Paula Mascarell, Javier García-Abellán, Leandro López, Melissa Bello-Pérez, Sergio Padilla, Felix Gutiérrez
Förderung
- Consorcio Centro de Investigación Biomédica en Red
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación
- European Union
Zitieren
APA
Masiá, M., Fernández-González, M., Ledesma, C., Losada-Echeberría, M., Gonzalo-Jiménez, N., Mascarell, P., García-Abellán, J., López, L., Bello-Pérez, M., Padilla, S., & Gutiérrez, F. (2025). Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf117
Vancouver
Masiá M, Fernández-González M, Ledesma C, Losada-Echeberría M, Gonzalo-Jiménez N, Mascarell P, et al. Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf117
BibTeX
@article{Masi2025,
author = {Masiá, Mar and Fernández-González, Marta and Ledesma, Christian and Losada-Echeberría, Maria and Gonzalo-Jiménez, Nieves and Mascarell, Paula and García-Abellán, Javier and López, Leandro and Bello-Pérez, Melissa and Padilla, Sergio and Gutiérrez, Felix},
title = {Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf117}
}
EUVIMED